Ping An Insurance Company of China, Ltd. is pleased to announce that its technology arm, Ping An Technology, has completed a prospective multi-center clinical trial for the world’s first intelligent optical coherence tomography retinal disease[1] screening system.
SHANGHAI and HONG KONG, May 15, 2019 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (“China Ping An”, “Ping An”, the “Group” or the “Company"; stock codes: HKEX 2318 and SSE 601318) is pleased to announce that its technology arm, Ping An Technology, has completed a prospective multi-center clinical trial for the world’s first intelligent optical coherence tomography (OCT) retinal disease[1] screening system.
The screening system is jointly developed by Ping An Technology and US-based Optovue, Inc. It is the first artificial intelligence (AI) imaging and screening system in the world that seamlessly integrates an OCT retinal imaging device and AI lesion detection software. The clinical trial was conducted at three well-known research institutions, the Eye and ENT Hospital of Fudan University in Shanghai, Shanghai First People’s Hospital of Shanghai Jiao Tong University, and Shanghai Tenth People’s Hospital of Tongji University.
Intelligent OCT facilitates disease detection accuracy and speed
OCT is a high-resolution, non-contact and non-invasive diagnostic technique that renders an in vivo cross-sectional view of the retina. As with most diagnostic tests, patient cooperation is a necessity. Moreover, OCT relies on the operator to correctly align the device on the patient’s eye for a proper retinal examination. The intelligent OCT retinal disease screening system developed by Ping An Technology focuses on the integration of an OCT retinal examination device with AI-powered screening software and applies the Generative Adversarial Network (GAN) technique in the model training process. Based on the in-depth technology of Ping An, the intelligent OCT retinal screening system conducts learning and analysis of hundreds of thousands of OCT data. The clinical trial was initiated in December 2018 at the above three research institutions and involved 784 study subjects. From the start of an OCT examination to a patient scan code used to generate an intelligent screening report, the entire process can be completed in three minutes. The findings suggested that the accuracy of tests on the samples by the system in image quality assessment, lesion detection, and referral urgency assessment were 99.2%, 98.6%, and 96.7% respectively, compared to the ground truth established by experts.
Regarding the published research findings, Professor Sun Xinghuai from the Eye & ENT Hospital of Fudan University, who is the designated Chairman of the Chinese Ophthalmological Society (COS) of Chinese Medical Association (CMA), said screening is one of the major parts of eye healthcare because a large number of eye diseases, especially disorders of the optic nerve on the retinal, can be “detected and treated earlier” by means of screening with favorable prognosis. This is why it is very important to improve the capability of primary medical institutions for screening fundus diseases. This research presented a highly accurate evaluation of the intelligent OCT fundus screening system developed by Ping An, which covers the quality of image acquisition, lesion detection and urgency, suggesting that AI will be extremely helpful to primary medical institutions in the future.
| [1] Retinal diseases are associated with progressive damage or degeneration of the eye macular, being the area in the center of the retina linked to eyesight or vision. |
The first-ever multi-center prospective research on AI-assisted ophthalmic medical products
A technical team from Ping An Technology and ophthalmologists from the three aforementioned research institutions jointly designed a rigorous diagnostic test research method to evaluate the performance of the system. An industry-leading multi-center, prospective research approach was adopted for this study. Unlike previous retrospective research methods commonly used in the industry, the prospective multi-center study was conducted with an emphasis towards using samples that were smaller and more efficient, and in strict compliance with medical ethics codes, to make breakthroughs with evidence-based performance for the intelligent OCT retinal disease screening system.
Xie Guotong, Chief Medical Scientist of Ping An Group, said: “This is the first time in the industry at home and abroad that multi-center prospective research on AI-assisted ophthalmic medical products has been conducted. The team of expert ophthalmologists led by the Eye and ENT Hospital of Fudan University, high-quality ophthalmic data and scientific research methods provided vital medical support for the accuracy and safety of ophthalmic AI models. With the strong healthcare ecosystem of Ping An Group, primary medical institutions will be empowered with high-quality ophthalmic AI models to assist in carrying out diagnosis and treatment at different levels.”
In recent years, Ping An has continued to advance the “finance + technology” and “finance + ecosystem” strategies, leveraging the leading AI technology and building a strong medical repository to establish a healthcare ecosystem. Based on AI technology, Ping An Technology integrates end-to-end disease whole-process solution matrixes in the fields of intelligent medical quality control, intelligent disease prediction, intelligent triage navigation, intelligent medical imaging and screening, intelligent paramedical diagnosis and treatment. The intelligent paramedical diagnosis and treatment model has covered 1000+ common diseases and it is expected that around 800 million potential patients will benefit from it.
About Ping An
Ping An Insurance (Group) Company of China, Ltd. (“Ping An”) is a world-leading technology-powered personal financial services group. With 184 million retail customers and 538 million Internet users, Ping An is one of the largest financial services companies in the world.
Ping An has two over-arching strategies ‘pan financial assets’ and ‘pan healthcare’, which focus on the provision of financial and healthcare services through our integrated financial services platform and our five ecosystems in financial services, healthcare, auto services, real estate services and Smart City services. Our ‘finance + technology’ and ‘finance ecosystems’ strategies aim to provide customers and internet users with innovative and simple products and services. As China’s first joint stock insurance company, Ping An Group is committed to upholding the highest standards of corporate reporting and corporate governance. The company is listed on the stock exchanges in Hong Kong and Shanghai.
Ping An ranked 10th in Forbes’ 2018 Global 2000, and it ranked 29th in Fortune Magazine’s 2018 Global 500 Leading Companies. Ping An also ranked 43rd in 2018 WPP Millward Brown’s BrandZTM Top 100 Most Valuable Global Brands. For more information, please visit www.pingan.cn
About Ping An Technology
Ping An Technology is the core technology arm of Ping An Group, using AI, cloud and other cutting-edge technologies to develop and operate mission-critical platforms and services that support financial services, medical health, automotive services, real estate services, and smart cities. With “Cloud Infinity” as its value proposition, Ping An Technology is actively practicing the corporate philosophy of “Professionalism makes life simpler”, and is determined to become a global leading “AI+Cloud” company.
For enquiries, please contact:
Gareth Hewett @ +852 68822027 or gareth.john@pingan.com.hk
View original content:http://www.prnewswire.com/news-releases/ping-an-completes-multi-center-clinical-trials-for-worlds-first-intelligent-oct-retinal-disease-screening-system-300850618.html
SOURCE Ping An Insurance (Group) Company of China, Ltd.
Company Codes: HongKong:2318, OTC-PINK:PNGAY, Shanghai:601318
